Ocugen Doses First Patient in Phase 3 Trial for Geographic Atrophy Gene Therapy — Ocugen, Inc.

Event summary

First patient dosed in global Phase 3 trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration (dAMD).
FDA granted RMAT designation to OCU410, accelerating development and review pathway.
Phase 3 trial design aligned with FDA, with Biologics License Application (BLA) filing anticipated in 2028.
OCU410 is a one-time subretinal gene therapy targeting multiple disease pathways, unlike approved complement inhibitors requiring ongoing injections.
Phase 2 data showed a 31% reduction in lesion growth with no serious adverse events related to OCU410.

The big picture

Ocugen's Phase 3 trial initiation for OCU410 marks a critical step in addressing geographic atrophy, a condition with limited treatment options. The RMAT designation and FDA alignment on trial design de-risk the regulatory pathway, potentially accelerating market entry. With a growing elderly population, the prevalence of GA is expected to rise, making OCU410's one-time gene therapy a strategic differentiator in the ophthalmology sector.

What we're watching

Regulatory Advantage: Whether RMAT designation will expedite OCU410's approval process and reduce time to market.
Clinical Efficacy: The pace at which Phase 3 trial results confirm the 31% lesion growth reduction observed in Phase 2.
Market Differentiation: How OCU410's multi-pathway approach will position it against existing complement inhibitors in the U.S.